Inactive Instrument

Odyssey Group International, Inc. Share Price Other OTC

Equities

ODYY

US67612C1027

Financials

Sales 2022	-	Sales 2023	-	Capitalization	11.06M 923M
Net income 2022	-8M -668M	Net income 2023	-5M -417M	EV / Sales 2022	-
Net Debt 2022	1.46M 122M	Net Debt 2023	2.11M 176M	EV / Sales 2023	-
P/E ratio 2022	-1.99 x	P/E ratio 2023	-1.95 x	Employees	-
Yield 2022 *	-	Yield 2023	-	Free-Float	0%

More Fundamentals * Assessed data

Chart Odyssey Group International, Inc.

Duration

Period

Style

Dynamic Chart

Latest news about Odyssey Group International, Inc.

Odyssey Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	23/03	CI
Oragenics, Inc. completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.	28/12	CI
Odyssey Health, Inc. Reports Earnings Results for the First Quarter Ended October 31, 2023	16/12	CI
Odyssey Health, Inc. Reports Earnings Results for the Full Year Ended July 31, 2023	31/23/31	CI
Odyssey Health, Inc. Announces the Resignation of John Gandolfo as Director	07/23/07	CI
Oragenics, Inc. entered into an Asset Purchase Agreement to acquire Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.	05/23/05	CI
Odyssey Health, Inc. Presents Concussion Treatment Data At the Military Health System Research Symposium -MHSRS	23/23/23	CI
Odyssey Health, Inc. executed a non- binding letter of intent to acquire Speranza Therapeutics, Inc.	28/23/28	CI
Odyssey Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023	15/23/15	CI
Odyssey Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	18/23/18	CI
Odyssey Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	18/23/18	CI
Odyssey Health, Inc. Appoints Jeffrey Conroy as Director	14/23/14	CI
Odyssey Health, Inc. to Develop Intranasal Field- Deliverable Nerve Agent Antidote	12/23/12	CI
Odyssey Health, Inc. Announces Resignation of Jeffrey Conroy as Director	07/23/07	CI
Odyssey Health, Inc. Reports Earnings Results for the First Quarter Ended October 31, 2022	15/22/15	CI

More news

Press releases Odyssey Group International, Inc.

Oragenics to Acquire Odyssey Health's Neurological Drug Technology Pipeline Including Concussion Drug Candidate	06/23/06	AQ
AM Best Upgrades Credit Ratings of Odyssey Group Holdings, Inc.'s Members	07/23/07	AQ
ODYSSEY HEALTH, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	05/23/05	AQ
Odyssey Health, Inc. Preparing for a Phase II Pharmaceutical Concussion Treatment	30/23/30	AQ
ODYSSEY HEALTH, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	18/23/18	AQ